PRO 140 in Treatment-Experienced HIV-1 Subjects
Trial details
- Registry ID
- NCT03902522
- Phase
- Phase 2, Phase 3
Drug identity checked against registry records
Also recorded as Humanized monoclonal antibody to CCR5; Leronlimab
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| PRO 140 in Treatment-Experienced HIV-1 SubjectsNCT03902522 | CytoDyn, Inc. | Phase 2, Phase 3 | Completed | 2020-05-18Actual |
| An Extension Protocol for Subjects Who Successfully Completed PRO140_CD02 or PRO140_CD02_Open Label StudyNCT02990858 | CytoDyn, Inc. | Phase 2, Phase 3 | Terminated | 2022-06Actual |
| A Study of Acute Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Stem-Cell TransplantationNCT02737306 | CytoDyn, Inc. | Phase 2 | Terminated | 2021-04-14Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |